Andrew Berens
Stock Analyst at Leerink Partners
(1.27)
# 3,622
Out of 4,974 analysts
95
Total ratings
46.43%
Success rate
-10.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $55.69 | +7.75% | 2 | Jul 28, 2025 | |
| COGT Cogent Biosciences | Maintains: Outperform | $16 → $18 | $13.05 | +37.93% | 5 | Jul 7, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $125 → $140 | $80.89 | +73.07% | 2 | Jun 24, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $7.83 | +14.94% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $3.44 | +74.42% | 3 | Apr 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Market Perform | $880 → $762 | $573.38 | +32.90% | 1 | Jan 28, 2025 | |
| OKUR OnKure Therapeutics | Initiates: Outperform | $33 | $2.70 | +1,122.22% | 1 | Dec 5, 2024 | |
| ZYME Zymeworks | Upgrades: Outperform | $10 → $25 | $15.05 | +66.11% | 10 | Nov 7, 2024 | |
| GILD Gilead Sciences | Upgrades: Outperform | $74 → $96 | $115.05 | -16.56% | 1 | Oct 21, 2024 | |
| AGIO Agios Pharmaceuticals | Downgrades: Market Perform | $60 → $56 | $35.96 | +55.73% | 11 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $86.64 | -9.97% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $48 | $67.47 | -28.86% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $9.90 | +182.97% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $81.70 | -3.30% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.75 | +1,442.86% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $6.99 | +257.65% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $6.46 | +519.20% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $2.72 | +2,363.24% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $4.93 | +305.68% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $6.94 | +260.23% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $13.60 | -41.18% | 7 | Jul 14, 2017 |
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $55.69
Upside: +7.75%
Cogent Biosciences
Jul 7, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $13.05
Upside: +37.93%
Nuvalent
Jun 24, 2025
Maintains: Outperform
Price Target: $125 → $140
Current: $80.89
Upside: +73.07%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $7.83
Upside: +14.94%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $3.44
Upside: +74.42%
Regeneron Pharmaceuticals
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $573.38
Upside: +32.90%
OnKure Therapeutics
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.70
Upside: +1,122.22%
Zymeworks
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $15.05
Upside: +66.11%
Gilead Sciences
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $115.05
Upside: -16.56%
Agios Pharmaceuticals
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $35.96
Upside: +55.73%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $86.64
Upside: -9.97%
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $67.47
Upside: -28.86%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $9.90
Upside: +182.97%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $81.70
Upside: -3.30%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.75
Upside: +1,442.86%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $6.99
Upside: +257.65%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $6.46
Upside: +519.20%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $2.72
Upside: +2,363.24%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $4.93
Upside: +305.68%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $6.94
Upside: +260.23%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $13.60
Upside: -41.18%